From East to West, combining a modern clinical approach and the latest biotechnologies, we develop best-in-class therapeutics. Our development model allows focused investment to quickly bring new medicines into mainstream standards, and within a few years, meet the needs of those who suffer.

We bring together the world’s top scientists in molecular biology, pharmacology and traditional medicines to carry out our research and development. Our management comprises senior executives img_what_01and seasoned entrepreneurs experienced in taking drug development from laboratory to market. They bring with them extensive experience in business and product development, project management, operations, legal and licensing and intellectual property patents. We focus on therapeutic areas with a strong differentiation factor such as neurology and ageing, it leverages the natural components of the medicine to pursue listing with health authorities, while implementing stringent control following Good Manufacturing Practice (GMP) standards for the drug’s production. These early market entries provided an early stream of revenues which have been reinvested into conducting further clinical development studies. Hence we have been accumulating further evidences regarding the drug’s safety and efficacy in mature markets.

The development of NeuroAiD, Moleac’s flagship product has followed this path. Despite its recent availability, NeuroAiD has become a product with global reach. It has undergone a considerable geographic expansion outside its home country, Singapore and is available internationally.


The Team

Since its creation in 2002, Moleac strengthens its teams each year to support its growth, which doubles each year.

Moleac’s European affiliate (Moleac Europe)  was created in Paris in 2008. The team’s diversity is a major asset, and today Moleac has more than forty employees from a dozen different countries.



May, one year after Nice venue (France), Moleac attends European Stroke Conference (ESC) in Vienna (Austria). This annual venue is a leading international conference of stroke related science worldwide.

April, Moleac attends European Stroke Organization Conference (ESOC) in Glasgow (UK). Founded in 2007, the European Stroke Organisation (ESO) in a Pan-European society of stroke researchers, national and regional stroke societies and lay people organisations. The main objective of this organisation is to reduce stroke incidence and impact by changing the ways stroke is perceived and treated.

February, a new paper on NeuroAiD have been published in the Journal of Stroke and Cerebrovascular Diseases : “Prognostic Factors and Treatment Effect in the CHIMES Study”. This new study provides important insights into patient response to NeuroAiD based on baseline prognostic factors, and confirms the results highlighted in CHIMES-Philippines paper.


October, Moleac attended 9th World Stroke Congress in Istanbul (Turkey). Turkey is a window through which Eastern Culture meets Western Culture, this represented a great opportunity to increase healthcare professionals’ knowledge on NeuroAiD.

July, a new publication on NeuroAiD is published in Neuroscience, and demonstrates how NeuroAiD can be beneficial in reducing the deleterious consequences induced by traumatic brain injury. This is the first publication on the pharmacological effects of NeuroAiD in traumatic brain injury.

May, Moleac attended European Stroke Conference (ESC) in Nice. This international conference on stroke was the opportunity to share the latest scientific progresses on NeuroAiD to neurologists and Neurosurgeons. Moleac organized a symposium led by Pr. Chen and Pr. Lazdunski, gathering more than 50 healthcare professionals and researchers for a detailed presentation of clinical and pharmacological progresses.

April, a third publication from the CHIMES Study is published in the International Journal of Stroke. This paper shows a significant favorable treatment effect of NeuroAiD in patient included with more predictors of poorer outcome. NeuroAiD have been launched in Spain, Portugal, Morocco, Kosovo and Ivory Coast, making NeuroAiD available in over 30 countries!


Moleac has just turned 10 years old! During this decade, many achievements have been done especially the expansion of NeuroAiD distribution to 29 countries in the world.

December 2013, new clinical data issued from CHIMES study on NeuroAiD, a treatment for post-stroke recovery, reducing early cardiovascular events and deaths by half after stroke, have been published in the Stroke journal.

August 2013, the CHIMES study results on functional recovery have been published in the Stroke journal.

Primary results of the CHIMES study were published online by the Stroke Journal in June. Printed version to appear in August’s edition. Researchers found NeuroAiD, a stroke treatment based on Traditional Chinese Medicine, increases the odds of achieving a better functional outcome.

May 2013, Moleac announces the results of the CHIMES clinical trial, an investigator-initiated study of NeuroAiD in Stroke Recovery.
The meta-analysis on the efficacy of NeuroAiD in post stroke recovery was published in March as part of an entire supplement in the Cerebrovascular Diseases journal. The supplement titled ‘New Developments in Neurorestorative Therapies from Natural Substances’ compiled five papers on the pharmacology of NeuroAiD and included a topic on ‘Drugs from Natural Substances: Why Study Them in Cerebral Infarction’ written by renowned Neurologist, Marie-Germaine Bousser.


July 2012, Moleac is happy to announce the opening of a representative office in Krakow (Poland) to orchestrate the operations in Eastern Europe, CIS and Balkans.

In May 2012, CHIMES trial completed patients’ inclusion, results are expected mid 2013.


Moleac completes its first profitable fiscal year. Moleac announces the beneficial effect of NeuroAiD (MLC901) in protecting the brain against global ischemia.

In June 2011, the team led by Prof. Micheal Lazdunski published a paper establishing NeuroAiD’s reparative effects on global cerebral ischemia.

In January 2011, Prof Michel Lazdunski, Vice President Research of Moleac, receives Gold Medal from Jung Foundation for Science and Research for his work on ion channels.


Moleac has been awarded the Emerging Company Award of the year 2010 by Biospectrum – the leading integrated media platform for the Life Science Industry in the Asia Pacific.

In January 2010, a team led by Prof. Lazdunski has established the novel mechanism of action of NeuroAiD showing that it increases neurogenesis, neurites outgrowth and synaptogenesis. The team also extended the scope of research on other neurological deficit diseases.


Moleac receives the Award of Singapore Entrepreneurial Company of the Year by Frost and Sullivan.Creation of new offices in Paris to support Moleac’s European expansion.
Launch of NeuroAiD in Iran, Iraq, Thailand and Pakistan.


Moleac incorporates European subsidiary in France.

Alliances with top research institutes and hospitals in China and Singapore.


Set up of NeuroAiD web platform to widen access to NeuroAiD. Initiation of CHIMES trial to measure the efficacy of NeuroAiD when initiated at the acute stage of stroke (completion in 2012).


Launch of NeuroAiD in Singapore.


Established exclusive in-licensing agreements from China for a credible drug pipeline with short time to market.Long term partnership aimed at building clinical evidence in the West and supporting sales development outside of China.

Leading Key Opinion Leaders from Asia, Europe, and Australia join the CHIMES initiative.

First clinical trials for TCM derived drugs involving leading Key Opinion Leaders in Europe


Moleac was set up in Singapore.Formation of Scientific Advisory Board comprising the world’s leading experts in pharmacology and molecular biology.

Alliances with top research institutes and hospitals in China and Singapore.